NYSE:JNJ

Johnson & Johnson - JNJ Stock Forecast, Price & News

$171.11

-0.68 (-0.40%)

(As of 08/5/2022 12:00 AM ET)

Add

Compare

Today's Range: $169.79
▼
$171.53
50-Day Range: $168.19
▼
$182.29
52-Week Range: $155.72
▼
$186.69

Volume: 5.24 million shs
Average Volume: 5.72 million shs
Market Capitalization: $449.88 billion

P/E Ratio: 24.91
Dividend Yield: 2.64%
Price Target: $189.89

Johnson & Johnson MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.56 Rating Score
Upside/Downside: 11.0% Upside
$189.89 Price Target
Short Interest: Healthy
0.52% of Shares Sold Short
Dividend Strength: Strong
Based on Four Factors
Sustainability: -1.98
Upright™ Environmental Score
News Sentiment: -0.26
Based on 22 Articles This Week
Insider Trading: Selling Shares
$8.44 M Sold Last Quarter
Proj. Earnings Growth: 4.48%
From $10.05 to $10.50 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.78 out of 5 stars

Medical Sector

68th out of 1,283 stocks

Pharmaceutical Preparations Industry

21st out of 615 stocks

2.3

Analyst's Opinion

Consensus Rating
Johnson & Johnson has received a consensus rating of Buy. The company's average rating score is 2.56, and is based on 5 buy ratings, 4 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $189.89, Johnson & Johnson has a forecasted upside of 11.0% from its current price of $171.11.
Amount of Analyst Coverage
Johnson & Johnson has only been the subject of 3 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
0.52% of the outstanding shares of Johnson & Johnson have been sold short.
Short Interest Ratio / Days to Cover
Johnson & Johnson has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Johnson & Johnson has recently decreased by 4.42%, indicating that investor sentiment is improving.

4.2

Dividend Strength

Dividend Yield
Johnson & Johnson pays a meaningful dividend of 2.64%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
Johnson & Johnson has been increasing its dividend for 61 years.
Dividend Coverage
The dividend payout ratio of Johnson & Johnson is 65.79%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Johnson & Johnson will have a dividend payout ratio of 43.05% next year. This indicates that Johnson & Johnson will be able to sustain or increase its dividend.

3.9

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Johnson & Johnson has received a 52.68% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Ustekinumab", "Clinical research services for physical health", "Rivaroxaban", "Daratumumab", "Ibrutinib", and "HIV medication" products. See details.
Environmental Sustainability
The Environmental Impact score for Johnson & Johnson is -1.98.

2.6

News and Social Media Coverage

News Sentiment
Johnson & Johnson has a news sentiment score of -0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.34 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 22 news articles for Johnson & Johnson this week, compared to 27 articles on an average week.
Social Mentions This Week
MarketBeat has tracked 12 reddit mentions for Johnson & Johnson this week, compared to 3 mentions on an average week.
Search Interest
196 people have searched for JNJ on MarketBeat in the last 30 days. This is an increase of 34% compared to the previous 30 days.
MarketBeat Follows
384 people have added Johnson & Johnson to their MarketBeat watchlist in the last 30 days. This is an increase of 540% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Johnson & Johnson insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,443,160.00 in company stock.
Percentage Held by Insiders
Only 0.35% of the stock of Johnson & Johnson is held by insiders.
Percentage Held by Institutions
68.78% of the stock of Johnson & Johnson is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Johnson & Johnson are expected to grow by 4.48% in the coming year, from $10.05 to $10.50 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Johnson & Johnson is 24.91, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 131.53.
Price to Earnings Ratio vs. Sector
The P/E ratio of Johnson & Johnson is 24.91, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 85.45.
Price to Earnings Growth Ratio
Johnson & Johnson has a PEG Ratio of 3.25. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Johnson & Johnson has a P/B Ratio of 5.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Johnson & Johnson (NYSE:JNJ) Stock

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Johnson & Johnson Price Performance

Johnson & Johnson stock traded down $0.68 during trading hours on Friday, hitting $171.11. 5,235,516 shares of the stock were exchanged, compared to its average volume of 5,716,105. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.14 and a current ratio of 1.42. The stock has a market capitalization of $449.88 billion, a P/E ratio of 24.91, a P/E/G ratio of 3.25 and a beta of 0.59. Johnson & Johnson has a 12 month low of $155.72 and a 12 month high of $186.69. The business's 50-day moving average is $175.21 and its two-hundred day moving average is $174.60.

Johnson & Johnson (NYSE:JNJ - Get Rating) last released its quarterly earnings results on Tuesday, July 19th. The company reported $2.59 EPS for the quarter, beating the consensus estimate of $2.57 by $0.02. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.14%. The business had revenue of $24.02 billion for the quarter, compared to analysts' expectations of $23.85 billion. During the same period in the prior year, the firm earned $2.48 earnings per share. Johnson & Johnson's revenue was up 3.0% compared to the same quarter last year. Equities research analysts expect that Johnson & Johnson will post 10.05 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd will be issued a $1.13 dividend. The ex-dividend date of this dividend is Monday, August 22nd. This represents a $4.52 annualized dividend and a yield of 2.64%. Johnson & Johnson's dividend payout ratio is currently 65.79%.

Analyst Upgrades and Downgrades

JNJ has been the subject of a number of research analyst reports. UBS Group cut their target price on shares of Johnson & Johnson from $185.00 to $180.00 in a research report on Thursday, July 21st. Wells Fargo & Company upped their price objective on shares of Johnson & Johnson from $190.00 to $195.00 and gave the company an "overweight" rating in a research report on Wednesday, July 13th. Morgan Stanley upped their price objective on shares of Johnson & Johnson from $173.00 to $174.00 and gave the company an "equal weight" rating in a research report on Friday, July 8th. SVB Leerink cut their price objective on shares of Johnson & Johnson from $200.00 to $194.00 in a research report on Wednesday, July 20th. Finally, StockNews.com raised shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research report on Tuesday, May 17th. Four research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Johnson & Johnson presently has an average rating of "Moderate Buy" and an average target price of $189.89.

Insider Activity at Johnson & Johnson

In related news, CAO Robert J. Decker sold 8,462 shares of the stock in a transaction that occurred on Thursday, May 26th. The shares were sold at an average price of $180.00, for a total value of $1,523,160.00. Following the transaction, the chief accounting officer now directly owns 15,473 shares in the company, valued at $2,785,140. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Johnson & Johnson news, CAO Robert J. Decker sold 8,462 shares of the stock in a transaction on Thursday, May 26th. The shares were sold at an average price of $180.00, for a total value of $1,523,160.00. Following the sale, the chief accounting officer now directly owns 15,473 shares in the company, valued at $2,785,140. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Kathryn E. Wengel sold 40,000 shares of the stock in a transaction on Friday, June 10th. The stock was sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the sale, the executive vice president now directly owns 71,311 shares of the company's stock, valued at approximately $12,336,803. The disclosure for this sale can be found here. 0.35% of the stock is currently owned by company insiders.

Receive JNJ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Johnson & Johnson and its competitors with MarketBeat's FREE daily newsletter.

JNJ Stock News Headlines

July 31, 2022 | marketbeat.com

Banana Boat recalls scalp sunscreen spray for cancer risk

The maker of Banana Boat sunscreen is recalling a scalp spray because it contains trace amounts of benzene, a chemical which can cause cancer with repeated exposure

July 26, 2022 | marketbeat.com

Drugmaker Teva latest to settle opioid lawsuits nationally

Drugmaker Teva has announced an agreement to settle lawsuits over the allegations that it helped fuel the U.S. opioid epidemic

July 26, 2022 | dividendstocks.com

Is Church & Dwight Co. Inc. (NYSE: CHD) a Buy for Dividend Investors? (JNJ)